Literature DB >> 28529592

Unique insight into microenvironmental changes in colorectal cancer: Ex vivo assessment of matrix metalloprotease-mediated molecular changes in human colorectal tumor tissue and corresponding non-neoplastic adjacent tissue.

Nicholas Willumsen1,2, Cecilie L Bager1, Anne-Christine Bay-Jensen1, Stephanie N Kehlet1, Henrik Harling3, Diana J Leeming1, Morten A Karsdal1, Lars N Jorgensen3.   

Abstract

Matrix metalloprotease (MMP)-mediated tissue remodeling is one of the malignant changes driving colorectal cancer. Measurement of altered MMP expression/activity is not sufficient to fully understand the effect of MMP-mediated tissue remodeling. Biomarkers are required that specifically reflect the dynamic processes of the MMP-mediated degradation of signature proteins from colorectal tissue. The aim of the present study was to profile and characterize the release of MMP-degraded type III collagen (C3M) and citrullinated and MMP-degraded vimentin (VICM) from tumor tissue and corresponding non-neoplastic adjacent tissue (NAT) in a human colorectal cancer ex vivo model. Colorectal tumor tissue and NAT biopsies from tissue removed during resection of colorectal cancer patients (n=13) were cut into pieces of 2 mm2 and cultured for 24 h in growth medium. C3M and VICM were evaluated by ELISA. As part of the characterization, C3M was determined subsequent to the tumor tissue being cleaved with recombinant MMP-2/-9 and trypsin. C3M was generated by MMP-2/-9, but not by trypsin. In addition, the level of C3M was significantly elevated in the conditioned medium from tumor tissues (3.7 ng/ml) compared with that observed in the conditioned medium from the NATs (2.2 ng/ml) and in the growth medium alone (1.9 ng/ml). The level of VICM was significantly elevated in the tumor tissues (0.51 ng/ml) and NATs (0.52 ng/ml) compared with that in the growth medium alone (0.03 ng/ml). No differences were detected between the tumor tissues and NATs. No correlation was observed between biomarker levels from the tumor tissue and corresponding NAT, and the biomarker levels did not correlate with tumor stage. In conclusion, the present study provided support of the concept that C3M and VICM are applicable as tools to investigate dynamic tissue changes of colorectal tumor tissue and corresponding NAT. By the assessment of these specific MMP-mediated molecular changes, the present study provides novel and relevant insight into the dynamic changes of colorectal tumor tissue and corresponding NAT.

Entities:  

Keywords:  ECM; MMP; biomarker; colorectal cancer; ex vivo; protein fingerprint

Year:  2017        PMID: 28529592      PMCID: PMC5431442          DOI: 10.3892/ol.2017.5900

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Vimentin is secreted by activated macrophages.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; David M Markovitz
Journal:  Nat Cell Biol       Date:  2003-01       Impact factor: 28.824

2.  The tumor microenvironment at a glance.

Authors:  Frances R Balkwill; Melania Capasso; Thorsten Hagemann
Journal:  J Cell Sci       Date:  2012-12-01       Impact factor: 5.285

Review 3.  Proteolytic networks in cancer.

Authors:  Steven D Mason; Johanna A Joyce
Journal:  Trends Cell Biol       Date:  2011-01-12       Impact factor: 20.808

4.  Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology.

Authors:  Efstathios Vassiliadis; Claudia P Oliveira; Mario R Alvares-da-Silva; Chen Zhang; Flair J Carrilho; Jose T Stefano; Fabiola Rabelo; Leila Pereira; Camila R Kappel; Kim Henriksen; Sanne Skovgård Veidal; Ben Vainer; Kevin L Duffin; Claus Christiansen; Diana J Leeming; Morten Karsdal
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

5.  Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells.

Authors:  Nicole F Steinmetz; Choi-Fong Cho; Amber Ablack; John D Lewis; Marianne Manchester
Journal:  Nanomedicine (Lond)       Date:  2011-02       Impact factor: 5.307

Review 6.  Remodelling the extracellular matrix in development and disease.

Authors:  Caroline Bonnans; Jonathan Chou; Zena Werb
Journal:  Nat Rev Mol Cell Biol       Date:  2014-12       Impact factor: 94.444

7.  In vivo-like growth of human tumors in vitro.

Authors:  A E Freeman; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

8.  MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients.

Authors:  A M J Langers; H W Verspaget; L J A C Hawinkels; F J G M Kubben; W van Duijn; J J van der Reijden; J C H Hardwick; D W Hommes; C F M Sier
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

9.  Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer.

Authors:  C Y Ngan; H Yamamoto; I Seshimo; T Tsujino; M Man-i; J-I Ikeda; K Konishi; I Takemasa; M Ikeda; M Sekimoto; N Matsuura; M Monden
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

10.  Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer.

Authors:  Nicholas Willumsen; Cecilie L Bager; Diana J Leeming; Victoria Smith; Claus Christiansen; Morten A Karsdal; David Dornan; Anne-Christine Bay-Jensen
Journal:  Cancer Med       Date:  2014-07-18       Impact factor: 4.452

View more
  2 in total

1.  Vastatin (the NC1 domain of human type VIII collagen a1 chain) is linked to stromal reactivity and elevated in serum from patients with colorectal cancer.

Authors:  Nicholas Willumsen; Lars Nannestad Jorgensen; Morten Asser Karsdal
Journal:  Cancer Biol Ther       Date:  2019-01-09       Impact factor: 4.742

Review 2.  Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy.

Authors:  Christina Jensen; Neel I Nissen; Claus S Von Arenstorff; Morten A Karsdal; Nicholas Willumsen
Journal:  J Exp Clin Cancer Res       Date:  2021-10-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.